on Mainz BioMed N.V.
Mainz Biomed Presents Cancer Detection Innovations at MEDICA 2025
Mainz Biomed N.V., a molecular genetics diagnostics company, is set to participate in the MEDICA 2025 event held in Düsseldorf, Germany from November 17-20. The company will showcase its advanced solutions for early cancer detection.
MEDICA, one of the leading global healthcare forums, is expected to draw over 80,000 visitors and 5,000 exhibitors from 70 countries. This event offers a platform for innovation and collaboration among healthcare experts and industry leaders.
Mainz Biomed's highlight includes the ColoAlert® screening test. This product is designed for the early detection of colorectal cancer using molecular stool-based methods. The company will also present emerging diagnostic solutions targeting early-stage cancers.
Interested parties can visit Mainz Biomed at the Rhineland-Pfalz joint booth in Hall 3, E92.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Mainz BioMed N.V. news